.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Fuji
Johnson and Johnson
Daiichi Sankyo
Moodys
Covington
Mallinckrodt
Accenture
Cerilliant
Argus Health

Generated: September 26, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Ether isonitriles and radiolabeled complexes thereof
Abstract:Ether-substituted isonitriles, Tc99m complexes thereof, and processes for myocardial tissue radioimaging using the Tc99m complexes.
Inventor(s): Bergstein; Paul L. (Norwood, MA), Subramanyam; Vinayakam (Wilmington, DE)
Assignee: E. I. Du Pont de Nemours and Company (Wilmington, DE)
Application Number:07/056,003
Patent Claims: 1. A compound which is an ether-substituted isonitrile of the formula: ##STR12## wherein A is a straight or branched chain alkylene group, and

R and R.sup.1 each independently is a straight or branched chain alkyl group or taken together are a straight or branched chain alkylene group,

provided that

(1) the total number of carbon atoms in A plus R in formula (I) is 4 to 6, provided further that when the total number of carbon atoms is 6, then the carbon atom alpha to the isonitrile group is a quaternary carbon, and still further provided that A is not (CH.sub.2).sub.3, and

(2) the total number of carbon atoms in A plus R plus R.sup.1 in formula (Ia) is 4 to 9.

2. The compound of claim I in sterile, non-pyrogenic form.

3. The compound of claim 1 wherein the ether-substituted isonitrile is of formula (Ia) and the total number of carbon atoms in A plus R plus R.sup.1 is 4 to 7.

4. The compound of claim 3 wherein the ether substituted isonitrile is ##STR13##

5. The compound of claim 3 in sterile, non-pyrogenic form.

6. The compound of claim 1 wherein the ether-substituted isonitrile is of formula (I).

7. The compound of claim 6 wherein the ether-substituted isonitrile is CNCH.sub.2 C(CH.sub.3).sub.2 OCH.sub.3.

8. The compound of claim 6 wherein the ether-substituted isonitrile is CNC(CH.sub.3).sub.2 CH.sub.2 OCH.sub.3.

9. The compound of claim 2 wherein the ether-substituted isonitrile is CNCH(CH.sub.3)CH.sub.2 OCH.sub.3.

10. The compound of claim 6 wherein the ether-substituted isonitrile is CNCH(CH.sub.3)CH.sub.2 OCH.sub.2 CH.sub.3.

11. The compound of claim 6 wherein the ether-substituted isonitrile is CNCH.sub.2 CH(CH.sub.3)OCH.sub.3.

12. The compound of claim 6 wherein the ether-substituted isonitrile is CNCH.sub.2 CH(CH.sub.3)OCH.sub.2 CH.sub.3.

13. The compound of claim 6 wherein the ether-substituted isonitrile is CNCH(CH.sub.3)CH(CH.sub.3)OCH.sub.3.

14. The compound of claim 6 wherein the ether-substituted isonitrile is CNCH.sub.2 CH(CH.sub.3)CH.sub.2 OCH.sub.3.

15. The compound of claim 6 wherein the ether-substituted isonitrile is CNCH.sub.2 CH.sub.2 CH(CH.sub.3)OCH.sub.3.

16. The compound of claim 6 wherein the ether-substituted isonitrile is CNC(CH.sub.3).sub.2 OCH.sub.2 CH.sub.3.

17. The compound of claim 6 wherein the ether-substituted isonitrile is CNC(CH.sub.3).sub.2 OCH.sub.3.

18. The compound of claim 6 wherein the ether-substituted isonitrile is CN(CH.sub.2).sub.2 OCH(CH.sub.3).sub.2.

19. The compound of claim 6 wherein the ether-substituted isonitrile is CN(CH.sub.2).sub.2 OCH.sub.2 CH.sub.3.

20. The compound of claim 6 wherein the ether-substituted isonitrile is CNCH.sub.2 CH(CH.sub.2 CH.sub.3)OCH.sub.3.

21. The compound of claim 6 wherein the ether-substituted isonitrile is CNCH(CH.sub.2 CH.sub.3)CH.sub.2 OCH.sub.3.

22. The compound of claim 6 wherein the ether-substituted isonitrile is CNCHCH.sub.3 OCH(CH.sub.3).sub.2.

23. The compound of claim 6 wherein the ether-substituted isonitrile is CNCH(CH.sub.3)CH.sub.2 CH.sub.2 OCH.sub.3.

24. The compound of claim 6 wherein the ether-substituted isonitrile is CNC(CH.sub.3)CH.sub.2 CH.sub.2 OCH.sub.3.

25. The compound of claim 6 in sterile, non-pyrogenic form.

26. The compound of any of claims 8 and 9 through 24 in sterile, non-pyrogenic form.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Deloitte
Queensland Health
Boehringer Ingelheim
Argus Health
Healthtrust
Julphar
Mallinckrodt
US Army
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot